Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.
Biomarkers
/ analysis
Early Diagnosis
Enteric Nervous System
/ chemistry
Exosomes
/ chemistry
Feces
/ chemistry
Humans
Inflammation
/ metabolism
Intestines
/ metabolism
Microbiota
Mouth
/ microbiology
Organ Specificity
Parkinson Disease
/ diagnosis
Permeability
Skin
/ chemistry
alpha-Synuclein
/ analysis
Biomarkers
Diagnosis
Idiopathic
Parkinson’s disease
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
04
2021
accepted:
16
07
2021
pubmed:
6
8
2021
medline:
25
3
2022
entrez:
5
8
2021
Statut:
ppublish
Résumé
Parkinson's disease (PD) ranks first in the world as a neurodegenerative movement disorder and occurs most commonly in an idiopathic form. PD patients may have motor symptoms, non-motor symptoms, including cognitive and behavioral changes, and symptoms related to autonomic nervous system (ANS) failures, such as gastrointestinal, urinary, and cardiovascular symptoms. Unfortunately, the diagnostic accuracy of PD by general neurologists is relatively low. Currently, there is no objective molecular or biochemical test for PD; its diagnosis is based on clinical criteria, mainly by cardinal motor symptoms, which manifest when patients have lost about 60-80% of dopaminergic neurons. Therefore, it is urgent to establish a panel of biomarkers for the early and accurate diagnosis of PD. Once the disease is accurately diagnosed, it may be easier to unravel idiopathic PD's pathogenesis, and ultimately, finding a cure. This review discusses several biomarkers' potential to set a panel for early idiopathic PD diagnosis and future directions.
Identifiants
pubmed: 34350555
doi: 10.1007/s12035-021-02500-z
pii: 10.1007/s12035-021-02500-z
doi:
Substances chimiques
Biomarkers
0
alpha-Synuclein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5517-5532Subventions
Organisme : programa de apoyo a la investigación científica y tecnológica
ID : SA1872-21
Organisme : programa de apoyo a la investigación científica y tecnológica
ID : SA1891-21
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of Parkinson’s disease. J Neurol 255(Suppl 5):18–32. https://doi.org/10.1007/s00415-008-5004-3
doi: 10.1007/s00415-008-5004-3
pubmed: 18787879
Horowitz MP, Greenamyre JT (2010) Gene-environment interactions in Parkinson’s disease: the importance of animal modeling. Clin Pharmacol Ther 88(4):467–474. https://doi.org/10.1038/clpt.2010.138[pii]
doi: 10.1038/clpt.2010.138[pii]
pubmed: 20811350
Allam MF, Del Castillo AS, Navajas RF-C (2005) Parkinson’s disease risk factors: genetic, environmental, or both? Neurol Res 27(2):206–208. https://doi.org/10.1179/016164105X22057
doi: 10.1179/016164105X22057
pubmed: 15829184
Hornykiewicz O (2006) The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70:9–15. https://doi.org/10.1007/978-3-211-45295-0_3
doi: 10.1007/978-3-211-45295-0_3
Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103(6):1661–1668. https://doi.org/10.1073/pnas.0509567103
doi: 10.1073/pnas.0509567103
pubmed: 16449387
pmcid: 1413649
Levy OA, Malagelada C, Greene LA (2009) Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis 14(4):478–500. https://doi.org/10.1007/s10495-008-0309-3
doi: 10.1007/s10495-008-0309-3
pubmed: 19165601
pmcid: 2754154
Beitz JM (2014) Parkinson’s disease: a review. Front Biosci (Schol Ed) 6:65–74. https://doi.org/10.2741/s415
doi: 10.2741/s415
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39. https://doi.org/10.1001/archneur.56.1.33
doi: 10.1001/archneur.56.1.33
pubmed: 9923759
Löhle M, Storch A, Reichmann H (2009) Beyond tremor and rigidity: non-motor features of Parkinson’s disease. J Neural Transm (Vienna) 116(11):1483–1492. https://doi.org/10.1007/s00702-009-0274-1
doi: 10.1007/s00702-009-0274-1
Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3):456–462. https://doi.org/10.1212/wnl.57.3.456
doi: 10.1212/wnl.57.3.456
pubmed: 11502913
Hornykiewicz O (2002) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17(3):501–508. https://doi.org/10.1002/mds.10115
doi: 10.1002/mds.10115
pubmed: 12112197
Rao SS, Hofmann LA, Shakil A (2006) Parkinson’s disease: diagnosis and treatment. Am Fam Physician 74(12):2046–2054
pubmed: 17186710
Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Garcia-Garcia A, Rodriguez-Rocha H (2021) Antioxidant therapeutics in Parkinson’s disease: current challenges and opportunities. Antioxidants 10(3):453. https://doi.org/10.3390/antiox10030453
Stoker TB, Barker RA (2020) Recent developments in the treatment of Parkinson’s disease. F1000Res 9:862. https://doi.org/10.12688/f1000research.25634.1
Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27–42. https://doi.org/10.1111/ene.14108
doi: 10.1111/ene.14108
pubmed: 31631455
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376. https://doi.org/10.1136/jnnp.2007.131045
doi: 10.1136/jnnp.2007.131045
pubmed: 18344392
pmcid: 18344392
Wu Y, Yao Q, Jiang GX, Wang G, Cheng Q (2020) Identification of distinct blood-based biomarkers in early stage of Parkinson’s disease. Neurol Sci 41(4):893–901. https://doi.org/10.1007/s10072-019-04165-y
doi: 10.1007/s10072-019-04165-y
pubmed: 31828678
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340
doi: 10.1002/mds.22340
pubmed: 19025984
Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, Martinez-Martin P (2020) The movement disorder society nonmotor rating scale: initial validation study. Mov Disord 35(1):116–133. https://doi.org/10.1002/mds.27862
doi: 10.1002/mds.27862
pubmed: 31571279
Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, Disease MTFotDoPs (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34(10):1464–1470. https://doi.org/10.1002/mds.27802
doi: 10.1002/mds.27802
pubmed: 31412427
Marsili L, Rizzo G, Colosimo C (2018) Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol 9:156. https://doi.org/10.3389/fneur.2018.00156
doi: 10.3389/fneur.2018.00156
pubmed: 29628907
pmcid: 5877503
Joutsa J, Gardberg M, Röyttä M, Kaasinen V (2014) Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 20(8):840–844. https://doi.org/10.1016/j.parkreldis.2014.04.019
doi: 10.1016/j.parkreldis.2014.04.019
pubmed: 24816002
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86(6):566–576. https://doi.org/10.1212/WNL.0000000000002350
doi: 10.1212/WNL.0000000000002350
pubmed: 26764028
Kalender WA (2006) X-ray computed tomography. Phys Med Biol 51(13):R29-43. https://doi.org/10.1088/0031-9155/51/13/R03
doi: 10.1088/0031-9155/51/13/R03
pubmed: 16790909
Emamzadeh FN, Surguchov A (2018) Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci 12:612. https://doi.org/10.3389/fnins.2018.00612
doi: 10.3389/fnins.2018.00612
pubmed: 30214392
pmcid: 6125353
Lotankar S, Prabhavalkar KS, Bhatt LK (2017) Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull 33(5):585–597. https://doi.org/10.1007/s12264-017-0183-5
doi: 10.1007/s12264-017-0183-5
pubmed: 28936761
pmcid: 5636742
Meyer PT, Frings L, Rücker G, Hellwig S (2017) F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 58(12):1888–1898. https://doi.org/10.2967/jnumed.116.186403
doi: 10.2967/jnumed.116.186403
pubmed: 28912150
Skowronek C, Zange L, Lipp A (2019) Cardiac 123I-MIBG scintigraphy in neurodegenerative Parkinson syndromes: performance and pitfalls in clinical practice. Front Neurol 10:152. https://doi.org/10.3389/fneur.2019.00152
doi: 10.3389/fneur.2019.00152
pubmed: 30863360
pmcid: 6399127
Rascol O, Schelosky L (2009) 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord 24(Suppl 2):S732–741. https://doi.org/10.1002/mds.22499
doi: 10.1002/mds.22499
pubmed: 19877202
Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95 https://doi.org/10.1067/mcp.2001.113989
Huss R (2015) Biomarkers. In: Atala A, Allickson JG (eds) Translational regenerative medicine. pp 235–241. https://doi.org/10.1016/b978-0-12-410396-2.00019-0
Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5(6):463–466. https://doi.org/10.1097/COH.0b013e32833ed177
doi: 10.1097/COH.0b013e32833ed177
pubmed: 20978388
pmcid: 20978388
Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1(2):182–188. https://doi.org/10.1602/neurorx.1.2.182
doi: 10.1602/neurorx.1.2.182
pubmed: 15717018
pmcid: 534923
Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, et al (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18(6):573–586. https://doi.org/10.1016/S1474-4422(19)30024-9
doi: 10.1016/S1474-4422(19)30024-9
pubmed: 30981640
Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, et al (2017) Biomarker-driven phenotyping in Parkinson’s disease: a translational missing link in disease-modifying clinical trials. Mov Disord 32(3):319–324. https://doi.org/10.1002/mds.26913
doi: 10.1002/mds.26913
pubmed: 28233927
pmcid: 5359057
Breydo L, Wu JW (1822) Uversky VN (2012) Α-synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta 2:261–285. https://doi.org/10.1016/j.bbadis.2011.10.002
doi: 10.1016/j.bbadis.2011.10.002
Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 102(5):1430–1435. https://doi.org/10.1073/pnas.0407146102
doi: 10.1073/pnas.0407146102
pubmed: 15671169
pmcid: 547830
Villar-Piqué A, Lopes da Fonseca T, Outeiro TF (2016) Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. J Neurochem 139(Suppl 1):240–255. https://doi.org/10.1111/jnc.13249
doi: 10.1111/jnc.13249
pubmed: 26190401
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, et al (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841. https://doi.org/10.1126/science.1090278
doi: 10.1126/science.1090278
pubmed: 14593171
Smith WW, Margolis RL, Li X, Troncoso JC, Lee MK, Dawson VL, Dawson TM, Iwatsubo T, et al (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 25(23):5544–5552. https://doi.org/10.1523/JNEUROSCI.0482-05.2005
doi: 10.1523/JNEUROSCI.0482-05.2005
pubmed: 15944382
pmcid: 6724982
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
doi: 10.1038/ncb748
pubmed: 11813001
Chahine LM, Beach TG, Brumm MC, Adler CH, Coffey CS, Mosovsky S, Caspell-Garcia C, Serrano GE, et al (2020) In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology 95(9):e1267–e1284. https://doi.org/10.1212/WNL.0000000000010404
Castanedo-Cazares JP, Rodriguez-Leyva I (2015) Skin biomarkers for neurodegenerative disease: a future perspective. Neurodegener Dis Manag 5(6):465–467. https://doi.org/10.2217/nmt.15.51
doi: 10.2217/nmt.15.51
pubmed: 26619251
Teves JMY, Bhargava V, Kirwan KR, Corenblum MJ, Justiniano R, Wondrak GT, Anandhan A, Flores AJ, et al (2017) Parkinson’s disease skin fibroblasts display signature alterations in growth, redox homeostasis, mitochondrial function, and autophagy. Front Neurosci 11:737. https://doi.org/10.3389/fnins.2017.00737
doi: 10.3389/fnins.2017.00737
pubmed: 29379409
Rodríguez-Leyva I, Calderón-Garcidueñas AL, Jiménez-Capdeville ME, Rentería-Palomo AA, Hernandez-Rodriguez HG, Valdés-Rodríguez R, Fuentes-Ahumada C, Torres-Álvarez B, et al (2014) α-Synuclein inclusions in the skin of Parkinson’s disease and parkinsonism. Ann Clin Transl Neurol 1(7):471–478. https://doi.org/10.1002/acn3.78
doi: 10.1002/acn3.78
pubmed: 25356418
pmcid: 4184776
Atarashi R, Sano K, Satoh K, Nishida N (2011) Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion 5(3):150–153. https://doi.org/10.4161/pri.5.3.16893
doi: 10.4161/pri.5.3.16893
pubmed: 21778820
pmcid: 3226039
Barria MA, Gonzalez-Romero D, Soto C (2012) Cyclic amplification of prion protein misfolding. Methods Mol Biol 849:199–212. https://doi.org/10.1007/978-1-61779-551-0_14
doi: 10.1007/978-1-61779-551-0_14
pubmed: 22528092
pmcid: 4068802
Manne S, Kondru N, Jin H, Serrano GE, Anantharam V, Kanthasamy A, Adler CH, Beach TG, et al (2020) Blinded RT-QuIC Analysis of α-Synuclein biomarker in skin tissue from Parkinson’s disease patients. Mov Disord 35(12):2230–2239. https://doi.org/10.1002/mds.28242
doi: 10.1002/mds.28242
pubmed: 32960470
Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, et al (2020) Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 78(1):30–40. https://doi.org/10.1001/jamaneurol.2020.3311
Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM, Onwubiko HA, Priola SA, et al (2008) Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods 5(3):211–212. https://doi.org/10.1038/nmeth0308-211
doi: 10.1038/nmeth0308-211
pubmed: 18309304
Wang N, Gibbons CH, Lafo J, Freeman R (2013) α-Synuclein in cutaneous autonomic nerves. Neurology 81(18):1604–1610. https://doi.org/10.1212/WNL.0b013e3182a9f449
doi: 10.1212/WNL.0b013e3182a9f449
pubmed: 24089386
pmcid: 3806913
Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, et al (2019) Discovery of volatile biomarkers of Parkinson’s disease from Sebum. ACS Cent Sci 5(4):599–606. https://doi.org/10.1021/acscentsci.8b00879
doi: 10.1021/acscentsci.8b00879
pubmed: 31041379
pmcid: 6487537
Kim YJ, Lee CM, Kim S, Jang JW, Lee SY, Lee SH (2019) Risk of Parkinson’s disease after colectomy: longitudinal follow-up study using a national sample cohort. J Neurol. https://doi.org/10.1007/s00415-019-09617-1
doi: 10.1007/s00415-019-09617-1
pubmed: 31802218
Felice VD, Quigley EM, Sullivan AM, O’Keeffe GW, O’Mahony SM (2016) Microbiota-gut-brain signalling in Parkinson’s disease: implications for non-motor symptoms. Parkinsonism Relat Disord 27:1–8. https://doi.org/10.1016/j.parkreldis.2016.03.012
doi: 10.1016/j.parkreldis.2016.03.012
pubmed: 27013171
Zhu X, Han Y, Du J, Liu R, Jin K, Yi W (2017) Microbiota-gut-brain axis and the central nervous system. Oncotarget 8 (32):53829–53838. https://doi.org/10.18632/oncotarget.17754
Vlassov AV, Magdaleno S, Setterquist R (1820) Conrad R (2012) Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 7:940–948. https://doi.org/10.1016/j.bbagen.2012.03.017
doi: 10.1016/j.bbagen.2012.03.017
Mathivanan S, Fahner CJ, Reid GE, Simpson RJ (2012) ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 40 (Database issue):D1241–1244. https://doi.org/10.1093/nar/gkr828
Proia P, Schiera G, Mineo M, Ingrassia AM, Santoro G, Savettieri G, Di Liegro I (2008) Astrocytes shed extracellular vesicles that contain fibroblast growth factor-2 and vascular endothelial growth factor. Int J Mol Med 21(1):63–67
pubmed: 18097617
Schiera G, Proia P, Alberti C, Mineo M, Savettieri G, Di Liegro I (2007) Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. J Cell Mol Med 11(6):1384–1394. https://doi.org/10.1111/j.1582-4934.2007.00100.x
doi: 10.1111/j.1582-4934.2007.00100.x
pubmed: 18205708
pmcid: 4401300
Pant S, Hilton H, Burczynski ME (2012) The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 83(11):1484–1494. https://doi.org/10.1016/j.bcp.2011.12.037
doi: 10.1016/j.bcp.2011.12.037
pubmed: 22230477
Howitt J, Hill AF (2016) Exosomes in the pathology of neurodegenerative diseases. J Biol Chem 291(52):26589–26597. https://doi.org/10.1074/jbc.R116.757955
doi: 10.1074/jbc.R116.757955
pubmed: 27852825
pmcid: 5207170
Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, et al (2014) Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 128(5):639–650. https://doi.org/10.1007/s00401-014-1314-y
doi: 10.1007/s00401-014-1314-y
pubmed: 24997849
pmcid: 4201967
Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 7:42. https://doi.org/10.1186/1750-1326-7-42
doi: 10.1186/1750-1326-7-42
pubmed: 22920859
pmcid: 3483256
Cao Z, Wu Y, Liu G, Jiang Y, Wang X, Wang Z, Feng T (2019) α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. Neurosci Lett 696:114–120. https://doi.org/10.1016/j.neulet.2018.12.030
doi: 10.1016/j.neulet.2018.12.030
pubmed: 30579996
Lynge Pedersen AM, Belstrøm D (2019) The role of natural salivary defences in maintaining a healthy oral microbiota. J Dent 80(Suppl 1):S3–S12. https://doi.org/10.1016/j.jdent.2018.08.010
doi: 10.1016/j.jdent.2018.08.010
pubmed: 30696553
Marsh PD, Do T, Beighton D (2000) Devine DA (2016) Influence of saliva on the oral microbiota. Periodontol 70(1):80–92. https://doi.org/10.1111/prd.12098
doi: 10.1111/prd.12098
Franzosa EA, Morgan XC, Segata N, Waldron L, Reyes J, Earl AM, Giannoukos G, Boylan MR, et al (2014) Relating the metatranscriptome and metagenome of the human gut. Proc Natl Acad Sci U S A 111(22):E2329-2338. https://doi.org/10.1073/pnas.1319284111
doi: 10.1073/pnas.1319284111
pubmed: 24843156
pmcid: 4050606
Schmidt TS, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, Wirbel J, Maistrenko OM, et al (2019) Extensive transmission of microbes along the gastrointestinal tract. Elife 8. https://doi.org/10.7554/eLife.42693
Mihaila D, Donegan J, Barns S, LaRocca D, Du Q, Zheng D, Vidal M, Neville C, et al (2019) The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function. PLoS ONE 14(6):e0218252. https://doi.org/10.1371/journal.pone.0218252
doi: 10.1371/journal.pone.0218252
pubmed: 31247001
pmcid: 6597068
Belibasakis GN, Bostanci N, Marsh PD, Zaura E (2019) Applications of the oral microbiome in personalized dentistry. Arch Oral Biol 104:7–12. https://doi.org/10.1016/j.archoralbio.2019.05.023
doi: 10.1016/j.archoralbio.2019.05.023
pubmed: 31153099
Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, et al (2013) Colonic inflammation in Parkinson’s disease. Neurobiol Dis 50:42–48. https://doi.org/10.1016/j.nbd.2012.09.007
doi: 10.1016/j.nbd.2012.09.007
pubmed: 23017648
Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, Antalis TM, Vogel SN, et al (2009) Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 106(39):16799–16804. https://doi.org/10.1073/pnas.0906773106
doi: 10.1073/pnas.0906773106
pubmed: 19805376
pmcid: 2744629
El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A (2002) Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 123(5):1607–1615. https://doi.org/10.1053/gast.2002.36578
doi: 10.1053/gast.2002.36578
pubmed: 12404235
Wilson CM, McGilligan K, Thomas DW (1988) Determination of fecal alpha 1-antitrypsin concentration by radial immunodiffusion: two systems compared. Clin Chem 34(2):372–376
doi: 10.1093/clinchem/34.2.372
Silva MT (2010) When two is better than one: macrophages and neutrophils work in concert in innate immunity as complementary and cooperative partners of a myeloid phagocyte system. J Leukoc Biol 87(1):93–106. https://doi.org/10.1189/jlb.0809549
doi: 10.1189/jlb.0809549
pubmed: 20052802
Hessian PA, Edgeworth J, Hogg N (1993) MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol 53(2):197–204
doi: 10.1002/jlb.53.2.197
Roth J, Goebeler M, Wrocklage V, van den Bos C, Sorg C (1994) Expression of the calcium-binding proteins MRP8 and MRP14 in monocytes is regulated by a calcium-induced suppressor mechanism. Biochem J 301(Pt 3):655–660. https://doi.org/10.1042/bj3010655
doi: 10.1042/bj3010655
pubmed: 8053890
pmcid: 1137038
Eue I, König S, Pior J, Sorg C (2002) S100A8, S100A9 and the S100A8/A9 heterodimer complex specifically bind to human endothelial cells: identification and characterization of ligands for the myeloid-related proteins S100A9 and S100A8/A9 on human dermal microvascular endothelial cell line-1 cells. Int Immunol 14(3):287–297. https://doi.org/10.1093/intimm/14.3.287
doi: 10.1093/intimm/14.3.287
pubmed: 11867565
Clohessy PA, Golden BE (1995) Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. Scand J Immunol 42(5):551–556. https://doi.org/10.1111/j.1365-3083.1995.tb03695.x
doi: 10.1111/j.1365-3083.1995.tb03695.x
pubmed: 7481561
Masson PL, Heremans JF, Schonne E (1969) Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med 130(3):643–658. https://doi.org/10.1084/jem.130.3.643
doi: 10.1084/jem.130.3.643
pubmed: 4979954
pmcid: 2138704
Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14(8):841–845. https://doi.org/10.1097/00042737-200208000-00005
doi: 10.1097/00042737-200208000-00005
pubmed: 12172403
Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, Lee AG (1992) Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 30(5):1238–1242. https://doi.org/10.1128/JCM.30.5.1238-1242.1992
doi: 10.1128/JCM.30.5.1238-1242.1992
pubmed: 1583125
pmcid: 265257
Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Faßbender K, Schäfer KH, Unger MM (2018) Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord 50:104–107. https://doi.org/10.1016/j.parkreldis.2018.02.022
doi: 10.1016/j.parkreldis.2018.02.022
pubmed: 29454662
pmcid: 29454662
Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S (2019) Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson’s disease. Front Neurosci 13:992. https://doi.org/10.3389/fnins.2019.00992
doi: 10.3389/fnins.2019.00992
pubmed: 31611762
pmcid: 6776883
Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 76(3):217–221. https://doi.org/10.1007/BF00687767
doi: 10.1007/BF00687767
pubmed: 2850698
Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, et al (2014) Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 127(2):235–241. https://doi.org/10.1007/s00401-013-1214-6
doi: 10.1007/s00401-013-1214-6
pubmed: 24240814
Yan F, Chen Y, Li M, Wang Y, Zhang W, Chen X, Ye Q (2018) Gastrointestinal nervous system α-synuclein as a potential biomarker of Parkinson disease. Medicine (Baltimore) 97(28):e11337. https://doi.org/10.1097/MD.0000000000011337
doi: 10.1097/MD.0000000000011337
Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, et al (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS ONE 6(12):e28032. https://doi.org/10.1371/journal.pone.0028032
doi: 10.1371/journal.pone.0028032
pubmed: 22145021
pmcid: 3228722
Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y, Blennerhassett PA, et al (2011) The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 23(12):1132–1139. https://doi.org/10.1111/j.1365-2982.2011.01796.x
doi: 10.1111/j.1365-2982.2011.01796.x
pubmed: 21988661
pmcid: 3413724
Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 108(38):16050–16055. https://doi.org/10.1073/pnas.1102999108
doi: 10.1073/pnas.1102999108
pubmed: 21876150
pmcid: 3179073
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167(6):1469-1480.e1412. https://doi.org/10.1016/j.cell.2016.11.018
doi: 10.1016/j.cell.2016.11.018
pubmed: 27912057
pmcid: 5718049
Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, et al (2015) Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18(7):965–977. https://doi.org/10.1038/nn.4030
doi: 10.1038/nn.4030
pubmed: 26030851
pmcid: 5528863
Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, et al (2011) Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 108(Suppl 1):4586–4591. https://doi.org/10.1073/pnas.1000097107
doi: 10.1073/pnas.1000097107
pubmed: 20571116
Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A, et al (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord 32:66–72. https://doi.org/10.1016/j.parkreldis.2016.08.019
doi: 10.1016/j.parkreldis.2016.08.019
pubmed: 27591074
pmcid: 27591074
Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28(10):1221–1227. https://doi.org/10.1136/gut.28.10.1221
doi: 10.1136/gut.28.10.1221
pubmed: 3678950
pmcid: 1433442
Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, et al (2009) Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28(1):88–93. https://doi.org/10.1016/j.clnu.2008.11.002
doi: 10.1016/j.clnu.2008.11.002
pubmed: 19108937
Neunlist M, Dobreva G, Schemann M (1999) Characteristics of mucosally projecting myenteric neurones in the guinea-pig proximal colon. J Physiol 517(Pt 2):533–546. https://doi.org/10.1111/j.1469-7793.1999.0533t.x
doi: 10.1111/j.1469-7793.1999.0533t.x
pubmed: 10332100
pmcid: 2269343
Clark A, Mach N (2017) The crosstalk between the gut microbiota and mitochondria during exercise. Front Physiol 8:319. https://doi.org/10.3389/fphys.2017.00319
doi: 10.3389/fphys.2017.00319
pubmed: 5437217
pmcid: 5437217
Ma J, Coarfa C, Qin X, Bonnen PE, Milosavljevic A, Versalovic J, Aagaard K (2014) mtDNA haplogroup and single nucleotide polymorphisms structure human microbiome communities. BMC Genomics 15:257. https://doi.org/10.1186/1471-2164-15-257
doi: 10.1186/1471-2164-15-257
pubmed: 24694284
pmcid: 4234434
Giles RE, Blanc H, Cann HM, Wallace DC (1980) Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci U S A 77(11):6715–6719. https://doi.org/10.1073/pnas.77.11.6715
doi: 10.1073/pnas.77.11.6715
pubmed: 6256757
pmcid: 350359
Moeller AH, Suzuki TA, Phifer-Rixey M, Nachman MW (2018) Transmission modes of the mammalian gut microbiota. Science 362(6413):453–457. https://doi.org/10.1126/science.aat7164
doi: 10.1126/science.aat7164
pubmed: 30361372
Yardeni T, Tanes CE, Bittinger K, Mattei LM, Schaefer PM, Singh LN, Wu GD, Murdock DG, et al (2019) Host mitochondria influence gut microbiome diversity: A role for ROS. Sci Signal 12(588). https://doi.org/10.1126/scisignal.aaw3159
Chahine LM, Stern MB, Chen-Plotkin A (2014) Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord 20(Suppl 1):S99-103. https://doi.org/10.1016/S1353-8020(13)70025-7
doi: 10.1016/S1353-8020(13)70025-7
pubmed: 24262199
pmcid: 4070332
Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62(10):1835–1838. https://doi.org/10.1212/01.wnl.0000127517.33208.f4
doi: 10.1212/01.wnl.0000127517.33208.f4
pubmed: 15159488
Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5(2):55–59. https://doi.org/10.1159/000112832
doi: 10.1159/000112832
pubmed: 18182779
Tian C, Liu G, Gao L, Soltys D, Pan C, Stewart T, Shi M, Xie Z, et al (2019) Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease. Transl Neurodegener 8:15. https://doi.org/10.1186/s40035-019-0155-y
doi: 10.1186/s40035-019-0155-y
pubmed: 31123587
pmcid: 6521422
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582(13):1783–1787. https://doi.org/10.1016/j.febslet.2008.04.057
doi: 10.1016/j.febslet.2008.04.057
pubmed: 18474236
Ueno SI, Hatano T, Okuzumi A, Saiki S, Oji Y, Mori A, Koinuma T, Fujimaki M, et al (2020) Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease. Ann Clin Transl Neurol 7(3):307–317. https://doi.org/10.1002/acn3.50990
doi: 10.1002/acn3.50990
pubmed: 32059082
pmcid: 7086006
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881. https://doi.org/10.1136/jnnp-2018-320106
doi: 10.1136/jnnp-2018-320106
pubmed: 30967444
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857–870. https://doi.org/10.1002/ana.24954
Lin YS, Lee WJ, Wang SJ, Fuh JL (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 8(1):17368. https://doi.org/10.1038/s41598-018-35766-w
doi: 10.1038/s41598-018-35766-w
pubmed: 30478269
pmcid: 6255914
Lin CH, Chiu MJ (2020) Author response: Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 95(14):658. https://doi.org/10.1212/WNL.0000000000010664
doi: 10.1212/WNL.0000000000010664
pubmed: 33020200
Sampedro F, Pérez-González R, Martínez-Horta S, Marín-Lahoz J, Pagonabarraga J, Kulisevsky J (2020) Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson’s disease. Parkinsonism Relat Disord 74:43–49. https://doi.org/10.1016/j.parkreldis.2020.04.009
doi: 10.1016/j.parkreldis.2020.04.009
pubmed: 32334380
Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):e1479–e1486. https://doi.org/10.1212/WNL.0000000000007179
doi: 10.1212/WNL.0000000000007179
pubmed: 30814322
Chung CC, Chan L, Chen JH, Bamodu OA, Hong CT (2020) Neurofilament light chain level in plasma extracellular vesicles and Parkinson’s disease. Ther Adv Neurol Disord 13:1756286420975917. https://doi.org/10.1177/1756286420975917
doi: 10.1177/1756286420975917
pubmed: 33335563
pmcid: 7724268
Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, et al (2017) Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 88(10):930–937. https://doi.org/10.1212/WNL.0000000000003680
doi: 10.1212/WNL.0000000000003680
pubmed: 28179466
pmcid: 5333515
Bäckström D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L, Lenfeldt N (2020) NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology 95(7):e827–e838. https://doi.org/10.1212/WNL.0000000000010084
doi: 10.1212/WNL.0000000000010084
pubmed: 32680941
pmcid: 7605503
Mizobuchi N, Hoseki J, Kubota H, Toyokuni S, Nozaki J, Naitoh M, Koizumi A, Nagata K (2007) ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell Struct Funct 32(1):41–50. https://doi.org/10.1247/csf.07001
doi: 10.1247/csf.07001
pubmed: 17507765
Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, et al (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20(2):173–188. https://doi.org/10.1385/jmn:20:2:173
doi: 10.1385/jmn:20:2:173
pubmed: 12794311
Zhang GL, Wang LH, Liu XY, Zhang YX, Hu MY, Liu L, Fang YY, Mu Y, et al (2018) Cerebral dopamine neurotrophic factor (CDNF) has neuroprotective effects against cerebral ischemia that may occur through the endoplasmic reticulum stress pathway. Int J Mol Sci 19(7):1905. https://doi.org/10.3390/ijms19071905
Volmer R, van der Ploeg K, Ron D (2013) Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci U S A 110(12):4628–4633. https://doi.org/10.1073/pnas.1217611110
doi: 10.1073/pnas.1217611110
pubmed: 23487760
pmcid: 3606975
Sousa-Victor P, Neves J, Cedron-Craft W, Ventura PB, Liao CY, Riley RR, Soifer I, van Bruggen N, et al (2019) MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nat Metab 1(2):276–290. https://doi.org/10.1038/s42255-018-0023-6
doi: 10.1038/s42255-018-0023-6
pubmed: 31489403
pmcid: 6727652
Galli E, Planken A, Kadastik-Eerme L, Saarma M, Taba P, Lindholm P (2019) Increased serum levels of mesencephalic astrocyte-derived neurotrophic factor in subjects with Parkinson’s disease. Front Neurosci 13:929. https://doi.org/10.3389/fnins.2019.00929
doi: 10.3389/fnins.2019.00929
pubmed: 31555085
pmcid: 6737037
Shang P, Zhang Y, Ma D, Hao Y, Wang X, Xin M, Zhu M, Feng J (2019) Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases. Expert Opin Ther Targets 23(11):967–986. https://doi.org/10.1080/14728222.2019.1691525
doi: 10.1080/14728222.2019.1691525
pubmed: 31711309
Abdolmaleki F, Kovanen PT, Mardani R, Gheibi-Hayat SM, Bo S, Sahebkar A (2020) Resolvins: emerging players in autoimmune and inflammatory diseases. Clin Rev Allergy Immunol 58(1):82–91. https://doi.org/10.1007/s12016-019-08754-9
doi: 10.1007/s12016-019-08754-9
pubmed: 31267470
Ren YZ, Zhang BZ, Zhao XJ, Zhang ZY (2020) Resolvin D1 ameliorates cognitive impairment following traumatic brain injury via protecting astrocytic mitochondria. J Neurochem 154(5):530–546. https://doi.org/10.1111/jnc.14962
doi: 10.1111/jnc.14962
pubmed: 31951012
Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, Campanelli F, Natale G, et al (2019) Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease. Nat Commun 10(1):3945. https://doi.org/10.1038/s41467-019-11928-w
doi: 10.1038/s41467-019-11928-w
pubmed: 31477726
pmcid: 6718379
Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 Suppl 3):S161-170. https://doi.org/10.1212/wnl.47.6_suppl_3.161s
doi: 10.1212/wnl.47.6_suppl_3.161s
pubmed: 8959985
Cipriani S, Chen X, Schwarzschild MA (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 4(5):701–712. https://doi.org/10.2217/bmm.10.94
doi: 10.2217/bmm.10.94
pubmed: 20945982
Hediger MA, Johnson RJ, Miyazaki H, Endou H (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20:125–133. https://doi.org/10.1152/physiol.00039.2004
doi: 10.1152/physiol.00039.2004
Yeum KJ, Russell RM, Krinsky NI, Aldini G (2004) Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 430(1):97–103. https://doi.org/10.1016/j.abb.2004.03.006
doi: 10.1016/j.abb.2004.03.006
pubmed: 15325916
de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58(5):797–800. https://doi.org/10.1002/ana.20663
doi: 10.1002/ana.20663
pubmed: 16240356
Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419–425. https://doi.org/10.1016/0361-9230(94)90285-2
doi: 10.1016/0361-9230(94)90285-2
pubmed: 8124580
Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 144(5):480–484. https://doi.org/10.1093/oxfordjournals.aje.a008954
doi: 10.1093/oxfordjournals.aje.a008954
pubmed: 8781463
Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 166(5):561–567. https://doi.org/10.1093/aje/kwm127
doi: 10.1093/aje/kwm127
pubmed: 17584757
O’Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A (2010) Plasma urate and Parkinson’s disease in women. Am J Epidemiol 172(6):666–670. https://doi.org/10.1093/aje/kwq195
doi: 10.1093/aje/kwq195
pubmed: 20682521
pmcid: 2950819
Gao X, O’Reilly É, Schwarzschild MA, Ascherio A (2016) Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86(6):520–526. https://doi.org/10.1212/WNL.0000000000002351
doi: 10.1212/WNL.0000000000002351
pubmed: 26764029
pmcid: 4753729
Cantoni GL (1953) The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. J Amer Chem Soc 74:2942–2943. https://doi.org/10.1021/ja01131a519
doi: 10.1021/ja01131a519
Silla Y, Varshney S, Ray A, Basak T, Zinellu A, Sabareesh V, Carru C, Sengupta S (2019) Hydrolysis of homocysteine thiolactone results in the formation of Protein-Cys-S-S-homocysteinylation. Proteins 87(8):625–634. https://doi.org/10.1002/prot.25681
doi: 10.1002/prot.25681
pubmed: 30869815
Hasan T, Arora R, Bansal AK, Bhattacharya R, Sharma GS, Singh LR (2019) Disturbed homocysteine metabolism is associated with cancer. Exp Mol Med 51(2):1–13. https://doi.org/10.1038/s12276-019-0216-4
doi: 10.1038/s12276-019-0216-4
pubmed: 30804341
Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U (2004) Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80(1):114–122. https://doi.org/10.1093/ajcn/80.1.114
doi: 10.1093/ajcn/80.1.114
pubmed: 15213037
Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Büttner T, Woitalla D, et al (1998) Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 40(4):225–227. https://doi.org/10.1159/000007984
doi: 10.1159/000007984
Sleeman I, Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo TK, Burn DJ (2019) Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson’s disease. J Parkinsons Dis 9(2):351–359. https://doi.org/10.3233/JPD-181535
doi: 10.3233/JPD-181535
pubmed: 30909247
pmcid: 6597987
McLeish MJ, Kenyon GL (2005) Relating structure to mechanism in creatine kinase. Crit Rev Biochem Mol Biol 40(1):1–20. https://doi.org/10.1080/10409230590918577
doi: 10.1080/10409230590918577
pubmed: 15804623
Eppenberger HM, Dawson DM, Kaplan NO (1967) The comparative enzymology of creatine kinases. I. Isolation and characterization from chicken and rabbit tissues. J Biol Chem 242(2):204–209
Wyss M, Smeitink J, Wevers RA, Wallimann T (1992) Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. Biochim Biophys Acta 1102(2):119–166. https://doi.org/10.1016/0005-2728(92)90096-k
doi: 10.1016/0005-2728(92)90096-k
pubmed: 1390823
Schlattner U, Tokarska-Schlattner M, Wallimann T (2006) Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 1762(2):164–180. https://doi.org/10.1016/j.bbadis.2005.09.004
doi: 10.1016/j.bbadis.2005.09.004
pubmed: 16236486
Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23(7):298–304. https://doi.org/10.1016/s0166-2236(00)01584-8
doi: 10.1016/s0166-2236(00)01584-8
pubmed: 10856939
Xu J, Fu X, Pan M, Zhou X, Chen Z, Wang D, Zhang X, Chen Q, et al (2019) Mitochondrial creatine kinase is decreased in the serum of idiopathic Parkinson’s disease patients. Aging Dis 10(3):601–610. https://doi.org/10.14336/AD.2018.0615
Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R (2015) Metabolomics for laboratory diagnostics. J Pharm Biomed Anal 113:108–120. https://doi.org/10.1016/j.jpba.2014.12.017
doi: 10.1016/j.jpba.2014.12.017
pubmed: 25577715
Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M (2008) Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 131(Pt 2):389–396. https://doi.org/10.1093/brain/awm304
doi: 10.1093/brain/awm304
pubmed: 18222993
Ahmed SS, Santosh W, Kumar S, Christlet HT (2009) Metabolic profiling of Parkinson’s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 16:63. https://doi.org/10.1186/1423-0127-16-63
doi: 10.1186/1423-0127-16-63
pubmed: 19594911
pmcid: 2720938
Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J, et al (2014) Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson’s disease. J Parkinsons Dis 4(3):549–560. https://doi.org/10.3233/JPD-140389
doi: 10.3233/JPD-140389
pubmed: 24927756
Yakhine-Diop SMS, Morales-García JA, Niso-Santano M, González-Polo RA, Uribe-Carretero E, Martinez-Chacon G, Durand S, Maiuri MC, et al (2020) Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease. Aging (Albany NY) 12(17):16690–16708. https://doi.org/10.18632/aging.103992
Shao Y, Li T, Liu Z, Wang X, Xu X, Li S, Xu G, Le W (2021) Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry. Mol Neurodegener 16(1):4. https://doi.org/10.1186/s13024-021-00425-8
doi: 10.1186/s13024-021-00425-8
pubmed: 33485385
pmcid: 7825156
Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M (2009) Metabolomic profiling in LRRK2-related Parkinson’s disease. PLoS ONE 4(10):e7551. https://doi.org/10.1371/journal.pone.0007551
doi: 10.1371/journal.pone.0007551
pubmed: 19847307
pmcid: 2761616
Grosshans H, Slack FJ (2002) Micro-RNAs: small is plentiful. J Cell Biol 156(1):17–21. https://doi.org/10.1083/jcb.200111033
doi: 10.1083/jcb.200111033
pubmed: 11781331
pmcid: 2173595
Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854. https://doi.org/10.1016/0092-8674(93)90529-y
Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, et al (2009) MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132(Pt 12):3342–3352. https://doi.org/10.1093/brain/awp300
doi: 10.1093/brain/awp300
pubmed: 19952055
Femminella GD, Ferrara N, Rengo G (2015) The emerging role of microRNAs in Alzheimer’s disease. Front Physiol 6:40. https://doi.org/10.3389/fphys.2015.00040
doi: 10.3389/fphys.2015.00040
pubmed: 25729367
pmcid: 4325581
Behbahanipour M, Peymani M, Salari M, Hashemi MS, Nasr-Esfahani MH, Ghaedi K (2019) Expression profiling of blood microRNAs 885, 361, and 17 in the patients with the Parkinson’s disease: integrating interaction data to uncover the possible triggering age-related mechanisms. Sci Rep 9(1):13759. https://doi.org/10.1038/s41598-019-50256-3
doi: 10.1038/s41598-019-50256-3
pubmed: 31551498
pmcid: 6760236
Wu J, Gao Y (2015) Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteomics 12(6):623–636. https://doi.org/10.1586/14789450.2015.1094380
doi: 10.1586/14789450.2015.1094380
pubmed: 26472227
Singh A, Kukreti R, Saso L, Kukreti S (2019) Oxidative stress: a key modulator in neurodegenerative diseases. Molecules 24(8). https://doi.org/10.3390/molecules24081583
Sato S, Mizuno Y, Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64(6):1081–1083. https://doi.org/10.1212/01.WNL.0000154597.24838.6B
doi: 10.1212/01.WNL.0000154597.24838.6B
pubmed: 15781836
Hirayama M, Nakamura T, Watanabe H, Uchida K, Hama T, Hara T, Niimi Y, Ito M, et al (2011) Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 17(1):46–49. https://doi.org/10.1016/j.parkreldis.2010.11.004
doi: 10.1016/j.parkreldis.2010.11.004
pubmed: 21106430
Tan L, Yu JT (2012) The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323(1–2):1–8. https://doi.org/10.1016/j.jns.2012.08.005
doi: 10.1016/j.jns.2012.08.005
pubmed: 22939820
Bai JH, Zheng YL, Yu YP (2020) Urinary kynurenine as a biomarker for Parkinson’s disease. Neurol Sci. https://doi.org/10.1007/s10072-020-04589-x
doi: 10.1007/s10072-020-04589-x
pubmed: 33180209
pmcid: 8159792
Luan H, Liu LF, Meng N, Tang Z, Chua KK, Chen LL, Song JX, Mok VC, et al (2015) LC-MS-based urinary metabolite signatures in idiopathic Parkinson’s disease. J Proteome Res 14(1):467–478. https://doi.org/10.1021/pr500807t
doi: 10.1021/pr500807t
pubmed: 25271123
Wang S, Kojima K, Mobley JA, West AB (2019) Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease. EBioMedicine 45:351–361. https://doi.org/10.1016/j.ebiom.2019.06.021
doi: 10.1016/j.ebiom.2019.06.021
pubmed: 31229437
pmcid: 6642358
Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, et al (2017) Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord 32(5):739–749. https://doi.org/10.1002/mds.26942
doi: 10.1002/mds.26942
pubmed: 28195358
pmcid: 28195358
Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K, Investigators P (2016) How stable are Parkinson’s disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 28:62–67. https://doi.org/10.1016/j.parkreldis.2016.04.027
doi: 10.1016/j.parkreldis.2016.04.027
pubmed: 27132498